相似文献
1
Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.
Pharmacogenomics. 2010 Jan;11(1):89-103. doi: 10.2217/pgs.09.154.
2
DMET microarray technology for pharmacogenomics-based personalized medicine.
Methods Mol Biol. 2010;632:99-124. doi: 10.1007/978-1-60761-663-4_7.
3
DMET-analyzer: automatic analysis of Affymetrix DMET data.
BMC Bioinformatics. 2012 Oct 5;13:258. doi: 10.1186/1471-2105-13-258.
4
DMET-Miner: Efficient discovery of association rules from pharmacogenomic data.
J Biomed Inform. 2015 Aug;56:273-83. doi: 10.1016/j.jbi.2015.06.005. Epub 2015 Jun 16.
5
Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment.
Pharmacogenet Genomics. 2014 Oct;24(10):477-85. doi: 10.1097/FPC.0000000000000075.
6
Pharmacogenomics of membrane transporters: past, present and future.
Pharmacogenomics. 2010 Apr;11(4):475-9. doi: 10.2217/pgs.10.22.
7
Gene expression variability in human hepatic drug metabolizing enzymes and transporters.
PLoS One. 2013 Apr 23;8(4):e60368. doi: 10.1371/journal.pone.0060368. Print 2013.
8
Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.
Pharmacol Ther. 2020 Nov;215:107627. doi: 10.1016/j.pharmthera.2020.107627. Epub 2020 Jul 11.
9
Epigenetic techniques in pharmacogenetics.
Methods Mol Biol. 2013;1015:179-88. doi: 10.1007/978-1-62703-435-7_11.
10
Leading the Way: Multi-Drug Resistance Protein (MDR1) and Clinical Pharmacology-Commentary on Kim et al.
Clin Pharmacol Ther. 2025 Jun;117(6):1562-1576. doi: 10.1002/cpt.3675.
引用本文的文献
1
Different perspectives on translational genomics in personalized medicine.
J Turk Ger Gynecol Assoc. 2022 Dec 8;23(4):314-321. doi: 10.4274/jtgga.galenos.2022.2021-11-4.
2
A resource for integrated genomic analysis of the human liver.
Sci Rep. 2022 Sep 7;12(1):15151. doi: 10.1038/s41598-022-18506-z.
3
Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia.
Pharmgenomics Pers Med. 2022 Feb 17;15:119-130. doi: 10.2147/PGPM.S346093. eCollection 2022.
4
Pharmacogenetics of Drugs Used in the Treatment of Cancers.
Genes (Basel). 2022 Feb 7;13(2):311. doi: 10.3390/genes13020311.
5
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Transl Clin Pharmacol. 2021 Sep;29(3):135-149. doi: 10.12793/tcp.2021.29.e14. Epub 2021 Sep 2.
6
Assessment of the clinical utility of pharmacogenetic guidance in a comprehensive medication management service.
J Am Coll Clin Pharm. 2020 Sep;3(6):1028-1037. doi: 10.1002/jac5.1250. Epub 2020 May 2.
7
Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.
Clin Pharmacokinet. 2021 Jan;60(1):89-102. doi: 10.1007/s40262-020-00913-y.
8
Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer.
PLoS One. 2019 Feb 28;14(2):e0212097. doi: 10.1371/journal.pone.0212097. eCollection 2019.
9
The Diversity of REcent and Ancient huMan (DREAM): A New Microarray for Genetic Anthropology and Genealogy, Forensics, and Personalized Medicine.
Genome Biol Evol. 2017 Dec 1;9(12):3225-3237. doi: 10.1093/gbe/evx237.
10
Minimum information required for a DMET experiment reporting.
Pharmacogenomics. 2016 Sep;17(14):1533-45. doi: 10.2217/pgs-2016-0015. Epub 2016 Aug 22.
本文引用的文献
1
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
Pharmacogenomics J. 2010 Jun;10(3):191-9. doi: 10.1038/tpj.2009.57. Epub 2009 Dec 29.
2
Genetic ancestry modifies pharmacogenetic gene-gene interaction for asthma.
Pharmacogenet Genomics. 2009 Jul;19(7):489-96. doi: 10.1097/FPC.0b013e32832c440e.
3
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.
Nat Genet. 2009 Jul;41(7):816-9. doi: 10.1038/ng.379. Epub 2009 May 31.
4
The Affymetrix DMET platform and pharmacogenetics in drug development.
Curr Opin Mol Ther. 2009 Jun;11(3):260-8.
5
In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions.
Expert Opin Drug Metab Toxicol. 2009 May;5(5):489-500. doi: 10.1517/17425250902911463.
6
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.
Pharmacogenomics. 2009 Feb;10(2):261-6. doi: 10.2217/14622416.10.2.261.
7
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.
Nat Clin Pract Oncol. 2009 Mar;6(3):153-62. doi: 10.1038/ncponc1303. Epub 2009 Jan 27.
8
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.
Nat Genet. 2009 Feb;41(2):221-7. doi: 10.1038/ng.296. Epub 2009 Jan 18.
9
Gene-environment interactions in asthma.
J Allergy Clin Immunol. 2009 Jan;123(1):3-11; quiz 12-3. doi: 10.1016/j.jaci.2008.10.046.
10
Cytochrome p-450 polymorphisms and response to clopidogrel.
N Engl J Med. 2009 Jan 22;360(4):354-62. doi: 10.1056/NEJMoa0809171. Epub 2008 Dec 22.
Zotero 插件